Sugai Kenji
Department of Child Neurology, National Center Hospital of Neurology and Psychiatry, National Center of Neurology and Psychiatry, 4-1-1 Ogawahigashi-cho, Kodaira, Tokyo 187-8551, Japan.
Brain Dev. 2010 Jan;32(1):64-70. doi: 10.1016/j.braindev.2009.09.019. Epub 2009 Oct 22.
Febrile seizures (FS) require both acute and chronic management. Acute management includes the treatment and differential diagnosis of FS and depend on the presence of seizures and a patient's level of consciousness upon arrival at hospital: a patient may be discharged after physical examination if there are no seizures and no alteration of consciousness; close observation and laboratory examinations may be indicated in cases when there are no seizures but the patient exhibits altered consciousness; and intravenous diazepam (DZP) is indicated if seizures persist. Central nervous system infections should be ruled out: if the patient has signs of meningeal irritation or increased intracranial pressure, disturbed consciousness for >1h, atypical seizures (partial seizures, seizures for >15 min, or recurrent seizures within 24h), cerebrospinal fluid examinations and/or computed tomography/magnetic resonance imaging are warranted. Chronic management includes the prevention of recurrent FS, counseling parents, and vaccination. Japanese guideline for the prevention of recurrent FS defines two types of warning factors (WF) for selecting patients who should be monitored carefully: factors related to the onset of epilepsy (EP factors) and recurrence of FS (FS factors). The EP factors consist of neurological or developmental abnormalities prior to the onset of FS, atypical seizures, and history of epilepsy in parents or siblings. The FS factors include the onset of FS before 1 year of age and a history of FS in one or both parents. The guideline recommends no medication for children with two or fewer past episodes of FS without WF; prophylactic DZP for children with prolonged FS exceeding 15 min, or two or more episodes of FS with two or more WF; and daily administration of phenobarbital or valproate for children in whom FS occur under 38 degrees C or who have prolonged FS despite prophylactic DZP. To reduce parents' anxiety, the natural history of FS should be explained. A child can be given all current vaccinations 2-3 months after the last episode of FS by his/her family doctor with information provided to the parents as to how to cope with fever and convulsions.
热性惊厥(FS)需要进行急性和慢性管理。急性管理包括热性惊厥的治疗和鉴别诊断,这取决于惊厥的发生情况以及患者入院时的意识水平:如果没有惊厥且意识无改变,患者在体格检查后可出院;如果没有惊厥但患者意识改变,则可能需要密切观察和实验室检查;如果惊厥持续,则需静脉注射地西泮(DZP)。应排除中枢神经系统感染:如果患者有脑膜刺激征或颅内压升高的迹象、意识障碍超过1小时、非典型惊厥(部分性惊厥、惊厥持续超过15分钟或24小时内反复惊厥),则需要进行脑脊液检查和/或计算机断层扫描/磁共振成像。慢性管理包括预防热性惊厥复发、为家长提供咨询以及接种疫苗。日本预防热性惊厥复发指南定义了两种警告因素(WF),用于选择应仔细监测的患者:与癫痫发作相关的因素(EP因素)和热性惊厥复发因素(FS因素)。EP因素包括热性惊厥发作前的神经或发育异常、非典型惊厥以及父母或兄弟姐妹有癫痫病史。FS因素包括1岁前发生热性惊厥以及父母一方或双方有热性惊厥病史。该指南建议,对于热性惊厥发作次数不超过两次且无警告因素的儿童,无需用药;对于热性惊厥持续时间超过15分钟或热性惊厥发作次数两次及以上且有两个及以上警告因素的儿童,预防性使用DZP;对于体温在38摄氏度以下发生热性惊厥或尽管预防性使用DZP但热性惊厥仍持续的儿童,每日服用苯巴比妥或丙戊酸盐。为减轻家长的焦虑,应向其解释热性惊厥的自然病程。在最后一次热性惊厥发作2 - 3个月后,家庭医生可为儿童接种所有现行疫苗,并向家长提供应对发热和惊厥的相关信息。